[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].

Abstract

Adenosine diphosphate (ADP)-induced platelet activation plays a pivotal role in the thrombocyte aggregation and pathogenesis of ischemic heart disease. The long-term benefit of dual anti-platelet therapy with ADP-receptor antagonists, such as clopidogrel, in combination with aspirin is well established for patients following coronary stent implantation. This review discusses latest developments in the field of ADP-receptor antagonists.

• Authors: N Gassanov, E Caglayan, E Erdmann, F Er
• Journal: Deutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 136 Issue 27 Pg. 1433-7 (Jul 2011) ISSN: 1439-4413 [Electronic] Germany
• Vernacular Title: ADP-Rezeptor-Antagonisten: neue Erkenntnisse zur Therapie und Prophylaxe der ischämischen Herzerkrankung.
• PMID: 21713722 (Publication Type: Journal Article, Review)
• Copyright: © Georg Thieme Verlag KG Stuttgart · New York.

Chemical References

• Platelet Aggregation Inhibitors
• Pyridines
• Receptors, Purinergic P2
• thienopyridine
• Adenosine Monophosphate
• cangrelor
• Clopidogrel
• Ticlopidine
• Aspirin

Topics

• Acute Coronary Syndrome (drug therapy, prevention & control)
• Adenosine Monophosphate (adverse effects, analogs & derivatives, therapeutic use)
• Angioplasty, Balloon, Coronary
• Aspirin (adverse effects, therapeutic use)
• Clopidogrel
• Combined Modality Therapy
• Humans
• Myocardial Ischemia (drug therapy, prevention & control)
• Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
• Pyridines (adverse effects, therapeutic use)
• Receptors, Purinergic P2 (drug effects)
• Stents
• Ticlopidine (adverse effects, analogs & derivatives, therapeutic use)